Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ginkgolide A is a highly active platelet activating factor (PAF) antagonist, classified as a diterpene lactone isolated from the leaves of the Ginkgo biloba tree. It belongs to the class of organic compounds known as ginkgolides and bilobalides, which are characterized by their rigid hexacyclic C20 trilactone structure. Ginkgolide A exhibits potential in treating various inflammatory and immunological disorders due to its ability to inhibit PAF-mediated processes. Its mechanisms include anti-inflammatory effects through inhibition of interleukins (IL-5, IL-13), MAPK pathway inhibition, toll-like receptor inhibition, and suppression of arachidonic acid inflammatory pathways. Additionally, it demonstrates anti-coagulant activity via PAF antagonism and anti-apoptotic effects through TNF receptor inhibition[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ginkgolide a.